Navigation Links
Champions Oncology Reports Financial Results for the Quarter Ended October 31, 2012
Date:12/13/2012

ref="http://www.championsoncology.com/">www.championsoncology.com.

About Champions Oncology, Inc.Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.  The Company's TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through its Personalized Oncology Solutions business.

This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2012 for a discussion of such risks, uncertain
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
2. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
3. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
4. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
5. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
6. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
7. 500 Oncology Providers Sign Up for Navigating Cancers Patient Engagement Portal
8. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
9. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
10. International Oncology Innovators Meeting in Hamburg
11. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Springs, FL (PRWEB) December 18, 2014 ... of the nation’s leading specialty pharmacies, has an ... serve as clinical pharmacy consultants for prescriber offices ... therapy expertise. , “We have a variety ... therapies. For example, those specializing in hepatitis C ...
(Date:12/19/2014)... Ed Bilsky, Ph.D., vice president for Research and ... the Neurosciences (CEN), and professor of pharmacology at the ... member of the prestigious Dana Alliance for Brain Initiatives ... receive this honor. , The Dana Alliance ... Foundation. Its mission is to advance public education ...
(Date:12/19/2014)... 2014 In contrast to traditional LED ... various colors, Valoya uses proprietary LED technology to incorporate ... possible uniformity which is critical in low proximity installations. ... accuracy throughout its lifetime which is up to four ... , "The investment cost was clearly higher when compared ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3
... PAREXEL International,Corporation (Nasdaq: PRXL ), a leading ... is among the first to conduct a,Chinese bridging ... in providing,Asian bridging studies, which are conducted in ... global plans, gather,relevant ethnic data in the U.S., ...
... coupled with broader range of application areas are expected to drive ... fueled by heightened interest in biopharmaceutical therapeutics, human and veterinary vaccine ... ... San Jose, CA (PRWEB) November 6, 2008 -- Cell culture is ...
... Conference Call Scheduled for November 6, 2008 at 10:00 a.m. ... (Nasdaq: SVNT ) today reported financial results for,the three ... for the,third quarter of 2008 was $18.2 million or $0.34 ... compared with a net loss of $14.6,million or $0.28 per ...
Cached Biology Technology:PAREXEL Expands Pioneering Asian Ethnobridging Expertise 2PAREXEL Expands Pioneering Asian Ethnobridging Expertise 3PAREXEL Expands Pioneering Asian Ethnobridging Expertise 4PAREXEL Expands Pioneering Asian Ethnobridging Expertise 5Cell/Tissue Culture Supplies Market to Reach $4.97 Billion by 2012, According to New Report by Global Industry Analysts 2Cell/Tissue Culture Supplies Market to Reach $4.97 Billion by 2012, According to New Report by Global Industry Analysts 3Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 7Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 8Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 9Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 10
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... of the Journal of the American Dietetic Association ... dietary quality among children; and relationships between eating habits ... of Eating Disorders , While vegetarians tend to eat ... be overweight or obese, they may be at increased ...
... 2009 Joseph H. Holmes Pioneer Awards will be presented on ... New York. The awards honor two recipients who have contributed ... science award will be presented to Lawrence Platt, MD, of ... California in Los Angeles, California. The basic science award will ...
... MD, will present the William J. Fry Memorial Lecture ... the 2009 AIUM Annual Convention in New York, New ... an AIUM member that has significantly contributed to the ... field. Alred Kurtz, MD, currently serves as a ...
Cached Biology News:News from the April 2009 Journal of the American Dietetic Association 2AIUM Presents 2009 Joseph H. Holmes Pioneer Awards 2AIUM presents 2009 William J. Fry Memorial Lecture award 2
... Recognizes K+ Cl- Cotransporter-1 ... no significant sequence homology ... CCC.,SPECIES REACTIVITIES: The immunogen ... in human, mouse, porcine ...
...
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
oligophrenin-1 (H-100)...
Biology Products: